NASDAQ
27.06.25 | 21:59
7,955 US-Dollar
-5,86 % -0,495
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.06. | Arcus Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| ARCUS BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 03.06. | H.C. Wainwright bekräftigt Kaufempfehlung für Arcus Biosciences-Aktie | 1 | Investing.com Deutsch | ||
| 02.06. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.05. | Arcus Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.05. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.04. | Forecasting The Future: 5 Analyst Projections For Arcus Biosciences | 2 | Benzinga.com | ||
| 26.02. | Arcus Biosciences stock rating upgraded to Buy at H.C. Wainwright | 23 | Investing.com | ||
| 25.02. | Arcus Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 25.02. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.02. | Arcus Biosciences stock target cut to $18 at H.C. Wainwright | 4 | Investing.com | ||
| 18.02. | Arcus Biosciences Shares Are Down Today: What's Going On? | 1 | Benzinga.com | ||
| 18.02. | Arcus Biosciences Prices 13.6 Mln Offering At $11.00/shr, Stock Slide In Pre-market | 1 | RTTNews | ||
| 18.02. | Arcus Biosciences advances cancer drug casdatifan post Gilead deal expiry | 5 | Investing.com | ||
| 18.02. | Arcus Biosciences stock dips after pricing $150M offering | 1 | Seeking Alpha | ||
| 18.02. | Arcus Biosciences treibt Krebsmedikament Casdatifan nach Auslaufen des Gilead-Deals voran | 16 | Investing.com Deutsch | ||
| 18.02. | Arcus Biosciences sets $11/share for $150M stock offering | 1 | Investing.com | ||
| 18.02. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.02. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.01. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.11.24 | Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update | 276 | Business Wire | HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| CUREVAC | 4,560 | -0,91 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
| STRYKER | 334,90 | -0,39 % | Kurs der Stryker-Aktie verharrt auf Vortags-Niveau (324,7763 €) | Am US-amerikanischen Aktienmarkt ist die Stryker-Aktie aktuell unauffällig. Der jüngste Kurs betrug 374,99 US-Dollar. Die Wertschätzung der Börsenteilnehmer für die Aktie von Stryker hat sich heute... ► Artikel lesen | |
| INFLARX | 0,696 | -0,43 % | InflaRx N.V. - 6-K, Report of foreign issuer | ||
| INTELLIA THERAPEUTICS | 8,366 | +2,50 % | CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? | ||
| VAXART | 0,433 | +2,90 % | Vaxart, Inc.: Vaxart Announces Preliminary Results of Annual Meeting of Stockholders | SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 108,55 | +1,26 % | Neurocrine Biosciences, Inc.: Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA (valbenazine) Capsules in Older Adults with Tardive ... | Data Add to Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients Treated with INGREZZA for Tardive Dyskinesia
Findings... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 45,050 | +0,92 % | Halozyme Says Bristol-Myers Squibb Gets EC Approval For Opdivo SC Developed With Halozyme's ENHANZE | NEW YORK CITY (dpa-AFX) - Halozyme Therapeutics, Inc. (HALO) Wednesday said that Bristol-Myers Squibb Company (BMY) received approval from the European Commission (EC) for a new subcutaneous... ► Artikel lesen | |
| XOMA ROYALTY | 23,400 | -0,85 % | Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right | EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (Nasdaq-CM:... ► Artikel lesen | |
| IMMATICS | 4,700 | +1,42 % | Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma | Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing... ► Artikel lesen | |
| MANNKIND | 3,214 | +0,19 % | MannKind Corp. Q1 Sales Increase | WASHINGTON (dpa-AFX) - MannKind Corp. (MNKD) released a profit for first quarter of $13.16 millionThe company's earnings totaled $13.16 million, or $0.04 per share. This compares with $10.63... ► Artikel lesen | |
| BEONE MEDICINES LTD ADR | 206,00 | 0,00 % | BeOne Medicines Ltd.: BeOne Medicines präsentiert wegweisende Onkologie-Pipeline beim R&D Day | Daten zu BRUKINSA, Sonrotoclax, BTK-CDAC und Kombinationstherapien, die den ungedeckten Bedarf von CLL-Patientengruppen umfassend adressieren Vielversprechende neue Daten aus der Pipeline für... ► Artikel lesen | |
| AC IMMUNE | 1,738 | +0,46 % | AC Immune SA: AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update | AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseasesPositive... ► Artikel lesen | |
| ESPERION | 0,870 | +2,81 % | Cascale Talks ESPR at Innovation Forum Sustainable Apparel Event in Amsterdam | NORTHAMPTON, MA / ACCESS Newswire / May 14, 2025 / Elisabeth von Reitzenstein, senior director of policy and public affairs at Cascale, recently took to the stage at Innovation Forum's Sustainable Apparel... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,169 | +0,93 % | ROCKET PHARMACEUTICALS, INC. - 8-K, Current Report |
ARCUS BIOSCIENCES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 7,955 Euro und damit -5,86 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCUS BIOSCIENCES INC finden Sie auf Wallstreet Online.